Condition

Advanced or Metastatic Solid Tumors

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 22 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials22
Recruiting3
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

22 shown
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsNCT07705334 · 2026-06-24
RECRUITING
A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963 · 2025-01-07
RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesNCT06395519 · 2024-05-13
RECRUITING
Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsNCT06781983 · 2025-01-24
ACTIVE_NOT_RECRUITING
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationNCT06448364 · 2024-05-09
TERMINATED
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid TumorsNCT06257758 · 2024-01-10
TERMINATED
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsNCT05907304 · 2023-08-17
ACTIVE_NOT_RECRUITING
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587 · 2023-04-18
ACTIVE_NOT_RECRUITING
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced MalignanciesNCT05753722 · 2023-03-03
COMPLETED
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid TumorsNCT05716295 · 2023-02-08
TERMINATED
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)NCT05594043 · 2022-12-21
COMPLETED
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130 · 2022-11-30
ACTIVE_NOT_RECRUITING
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684 · 2022-10-06
TERMINATED
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)NCT05382325 · 2022-06-16
ACTIVE_NOT_RECRUITING
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLCNCT04430933 · 2021-12-06
WITHDRAWN
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)NCT05017012 · 2021-09-21
COMPLETED
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid TumorsNCT04875806 · 2021-06-30
TERMINATED
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor CancerNCT04586270 · 2020-10-15
TERMINATED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469 · 2019-05-29
COMPLETED
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNCT03665285 · 2018-10-01
COMPLETED
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid TumorsNCT03454243 · 2018-02-15
TERMINATED
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast CancerNCT00748553 · 2008-09-01
COMPLETED

Trial status mix

TERMINATED7
COMPLETED6
ACTIVE_NOT_RECRUITING5
RECRUITING3
WITHDRAWN1

Phase mix

PHASE121
PHASE28
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.